Navigation Links
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator
Date:11/13/2009

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator. Kim Eldridge, Registered Nurse, with over 10 years of clinical experience in complex wound care, is a pioneer in the field of wound care; and is dedicated to providing the highest standards of care, improving clinical outcomes, emphasizing patient education, and ensuring healthcare accessibility and cost-efficiency.

(PRWEB) November 13, 2009 --

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator.

Kim Eldridge, Registered Nurse, was born and raised in Meridian, Mississippi, and has over 10 years of clinical experience in complex wound care. Her commitment to provide the highest standards of wound care, while improving clinical outcomes and emphasizing patient education, and her passion for ensuring healthcare accessibility and cost-efficiency, make Kim a pioneer in the field of wound care.

Kim has been a surgical nurse for over 17 years. She works exclusively with a general surgeon who specializes in wound care, hyperbaric therapy, and limb salvage. She provides surgical wound care in both acute and long term settings, and also consults for major wound care companies and organizations nationwide. She has published several posters and articles in the field of wound care education. Kim is a Registered Nurse First Assistant, and is a certified surgical, foot care and wound care nurse.

Maggie Jankowski, COO of Wake Pharma US, Inc. commented, “Kim Eldridge has been an invaluable resource to the Wound Be Gone® brand. Her clinical insight and experience has been a tremendous asset to our development team. We believe that Kim Eldridge, RN, will help us accelerate the growth of our product line.”

Kim Eldridge stated, “I am very pleased to accept the position of Coordinator & Clinical Wound Specialist Educator and to have the opportunity to contribute to the company’s clinical mission. My clinical experience with Wound Be Gone® has produced impressive results with improved wound healing trajectories. Wound Be Gone® is placing wound care into the hands of people who might otherwise suffer or whose wound problems might escalate to need for expensive, invasive medical intervention.”

Wound-Be-Gone® is a novel hydrophilic gel that has demonstrated enhanced wound healing in varied clinical settings with both acute and chronic wounds. The mechanism of action is related to a decrease in inflammatory mediators due to the active scavenging of oxygen free radicals. Visit www.woundbegone.com for more details.

About Wake Pharma US, Inc:

Wake Pharma US, Inc. is an innovative and international company with its own manufacturing facility located in the Czech Republic (European Union). Wake Pharma US, Inc specializes in developing, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharma US, Inc please visit our website at www.wakepharmaus.com

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3194034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator 
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: